Already 1994 the 4 S Study, the first study was published, a Scandinavian study with 4444 patients for 5 years showing effects of simvastatin on hard end points, heart infarctions – and in diabetic patients there was a 55% drop of heart attacks. The lipid hypothesis is accepted, and
Latinos who worry about having enough food to eat, so called food insecurity, report having a poorer diet and exhibit worse glycemic control ,HbA1c, than tose who are not worried about having sufficient food to surivive, according to a study
These findings suggest that food insecurity
Gut-hormone-based mewdication used to treat diabetes, such as GLP-1-receptor agonists, have also been show to reduce body weight. Researchers have ben working to understand how.
This study sheds light on how these medications alter the brain´s response to food, possibly reducing
Type 1 diabetes patients younger than 40 may be candidates for statin use, as guidelines recommend after age 40, researchers suggested.
Under the American Heart Association/American College of Cardiology definition,
• the 10-year cardiovascular risk was about 5% for type 1 diabetes patients
Treatment with sitagliptin, a DPP4-inhibitor, versus placebo for median 3 years in 14 671 patients with type 2 diabetes and established cardiovascular (CV) disease showed non-inferiority for the primary composite CV endpoint of the trial evaluating CV outcomes (TECOS) in the
Today's Top News
Medtronic touts data in support of FDA approval of the latest MiniMed glucose monitor
Medtronic presented data in support of FDA approval of its MiniMed 640G glucose monitor and pump at the ongoing annual meeting of the American Diabetes
Tidningen DiabetologNytt skickas i början av denna vecka ut till 4000 medlemmar i Svensk Förening för Diabetologi.
Du som väntar på Din tidning eller Du som bara vill läsa den på www
Gå in på www.dagensdiabetes.se
så ligger den där överst till vänster, klickbar och utan lösenord
eller gå in på nedan www så
Press release from Sanofi ELIXA is the first event-driven cardiovascular outcomes study to provide data for a GLP-1 receptor agonist - Full results for ELIXA study presented at American Diabetes Association's 75th Scientific Sessions - Paris, France - June 8, 2015 - Sanofi announced today the
Diabetes education and support are needed throughout a persons´ life, not just at diagnosis. It has always been acknowledged as a key part of diabetes care.
Scientific evidence supports a structure for education. We know that education works. Research has shown that diabetes education and
Four experts review the latest advances in islet transplantation, including results from a major multicenter, phase 3 registration trial. T
“We are now planning the FDA submission of a Biological License Application for islet transplantation,” said Dr. Ricordi. “If successful, it
Banting Medal winner investigating many roles of adiponectin, Philipp E. Scherer, PhD
Adipose tissue is emerging as one of the most potent regulatory tissues in the human body. There’s much more to it than fat and obesity.
“No other tissue has been so maligned for so long,” said Philipp E.
What is the optimal treatment for patients with diabetes and osteitis or osteomyelitis of a bone in the diabetic foot, surgical or medical and is there a role for hyperbaric therapi in treating the diabetic foot ulcer?
There is strong evidence on all sides of these questions, and even
If we take a look at all the posters and oral presentations the following search words are the most popular topics, in number of abstracts.
It may give some hints about today´s main topic for the diabetes community as well as the challenges for the future
Listing from highest
85 number of
The artificial pancreas (AP) for children and adolescents is not a reality. Not yet. But closed loop technology is improving and moving toward. Many investigators see device submission and approval as a matter of time.
One of the most exciting things in the AP world in the last year is
Newer formulations of insulin promise to be effective but also more costly than the insulin already on the market. New insulins coming up, more long-working Tresiba, higher concentration of the new Lantus U 300, new Humalog U-200 and so on.
Are they really worth it?
Con; New products are
Diabetes medications will continue to rise, the cost of developing and introducing new medication is also on the rise. In terms of diabetes drugs, we have seen very large studies, trials and the lengthening cost money, which suggest larger than average development costs.
At a Meeting
BOSTON ADA Meeting
We are gathered to share cutting-edge research, treatment recommendation toward a better life for people with diabetes – in the long run a cure for diabetes.
In US 23 million people, children and adults, have diabetes.
The ADA Meeting started 75 years ago – so this year a year
I går kväll publicerades resultaten från IMPROVE-IT, [IMProved Reduction of Outcomes: VYTORIN Efficacy International Trial] i New England Journal of Medicine (NEJM).
Det är första gången som
BOSTON, MA — The IMPROVE-IT study, the large cardiovascular-outcomes trial that showed a clinical benefit to adding ezetimibe (Zetia, Merck/Schering Plough) to statin therapy in post–acute coronary syndrome (ACS) patients, is now published.
First presented during the late-breaking
Ladda hem rapporten 156 sidor
Som ett led i Sveus arbete med utveckling av nya uppföljningssystem har analyser utförts på
Pressmeddelande • 2015-06-03 08:03 CEST
The timing of the diagnosis and the start of treatment appeared more important than the actual intensity of treatment, the
Sida 7 av 8